Lilly To Acquire Kelonia Therapeutics To Advance In Vivo Car-T Cell Therapies
Eli Lilly and Co LLY.N:
LILLY TO ACQUIRE KELONIA THERAPEUTICS TO ADVANCE IN VIVO CAR-T CELL THERAPIES
ELI LILLY - UNDER TERMS OF AGREEMENT, LILLY WILL ACQUIRE KELONIA, AND KELONIA SHAREHOLDERS WILL RECEIVE UP TO $7.00 BILLION IN CASH
ELI LILLY: TRANSACTION IS EXPECTED TO CLOSE IN SECOND HALF OF 2026
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
TSLA Q1 Earnings Preview: Tesla Snaps 8-Week Slump—Now Buy the Dip or Wait?

AI Chip Startup Cerebras Refiles for IPO, Testing Nvidia’s Pricing Power

Intel Q1 Earnings Preview: Triple Test of CPU, 18A Yields and Foundry Orders

Allbirds Ditches Sneakers and Pivots to AI Computing - Is BIRD Stock Still Worth Buying After a 600% Surge?

Bitcoin Breaks $78,000 Amid U.S.-Iran Conflict, Can It Return to $100,000 in 2026?

Tradingkey







